Edition:
United States

Bellicum Pharmaceuticals Inc (BLCM.OQ)

BLCM.OQ on NASDAQ Stock Exchange Global Market

3.59USD
3:59pm EST
Change (% chg)

$-0.16 (-4.27%)
Prev Close
$3.75
Open
$3.75
Day's High
$3.80
Day's Low
$3.59
Volume
75,982
Avg. Vol
99,639
52-wk High
$10.23
52-wk Low
$3.59

Latest Key Developments (Source: Significant Developments)

Bellicum Pharmaceuticals Appoints Atabak Mokari As CFO
7:00am EST 

Dec 13 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS APPOINTS ATABAK MOKARI AS CHIEF FINANCIAL OFFICER.BELLICUM PHARMACEUTICALS INC - APPOINTMENT OF ATABAK MOKARI AS CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 19.BELLICUM PHARMACEUTICALS INC - MOKARI JOINS BELLICUM FROM IRIDEX CORPORATION.  Full Article

Bellicum Pharma Files For Mixed Shelf Of Upto $150 Million
Tuesday, 7 Aug 2018 06:13pm EDT 

Aug 7 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Bellicum Pharmaceuticals Says On July 13, Co, CFO, Alan Musso Entered Separation Agreement After Which Musso Resigned Effective Aug 31
Monday, 16 Jul 2018 04:46pm EDT 

July 16 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM PHARMACEUTICALS SAYS ON JULY 13, CO, CFO, ALAN MUSSO ENTERED SEPARATION AGREEMENT AFTER WHICH MUSSO RESIGNED EFFECTIVE AUGUST 31 - SEC FILING.  Full Article

Bellicum Announces Clinical Hold Lifted On U.S. Studies Of BPX-501
Wednesday, 11 Apr 2018 04:17pm EDT 

April 11 (Reuters) - Bellicum Pharmaceuticals Inc ::BELLICUM ANNOUNCES CLINICAL HOLD LIFTED ON U.S. STUDIES OF BPX-501.FDA CLINICAL HOLD DID NOT AFFECT BP-004 REGISTRATIONAL TRIAL IN EUROPE, WHICH IS FULLY ENROLLED.LIFT OF CLINICAL HOLD FOLLOWS CONSULTATION WITH FDA & AGREEMENT ON AMENDMENTS TO STUDY PROTOCOLS.BELLICUM WILL BE WORKING WITH U.S. CLINICAL SITES TO RESUME PATIENT RECRUITMENT BASED ON AMENDED PROTOCOLS.  Full Article

Bellicum reports qtrly earnings per share loss‍ $0.71​
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum reports third quarter 2017 financial results.Bellicum Pharmaceuticals Inc qtrly earnings per share loss‍ $0.71​.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Bellicum announces appointment of Rick Fair as CEO
Tuesday, 31 Jan 2017 07:00am EST 

Bellicum Pharmaceuticals Inc : Bellicum announces appointment of Rick Fair as chief executive officer in preparation for commercialization of bpx-501 and next phase of growth . Bellicum pharmaceuticals - fair joins Bellicum from Genentech/Roche, where he was senior vice president, head of oncology global product strategy .Bellicum Pharmaceuticals Inc - Fair succeeds Tom Farrell, who will serve as an advisor to company during transition.  Full Article